EICHORPublic-registry site landscape for NCT07012395, “A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis”, a Ulcerative Colitis study sponsored by Spyre Therapeutics, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07012395 (registry record) |
| Study title | A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis |
| Official title | Phase 2 Platform Trial to Assess the Efficacy and Safety of Long-acting Antibodies as Single Agents and in Combinations for Moderately to Severely Active Ulcerative Colitis |
| Sponsor | Spyre Therapeutics, Inc. |
| Condition(s) | Ulcerative Colitis; Inflammatory Bowel Diseases; Colitis; Colitis, Ulcerative |
| Phase | PHASE2 |
| Listed sites | 243 |
| Site countries | United States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, Croatia, Czechia |
Patient-friendly overview of this study: eichor.com/study/NCT07012395.
Eichor generates a preliminary site-risk snapshot for NCT07012395 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Ulcerative Colitis trials
← Eichor home · All tracked trials · Ulcerative Colitis studies · Weekly briefs
